Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 946 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08. Following the sale, the chief financial officer now owns 109,474 shares in the company, valued at $18,827,338.52. The trade was a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $146,343.98.

Natera Stock Performance

Shares of NTRA opened at $167.61 on Monday. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The stock has a market capitalization of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company’s fifty day moving average is $166.20 and its two-hundred day moving average is $136.43.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.95) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on NTRA shares. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. TD Cowen increased their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group boosted their price objective on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Finally, Craig Hallum lifted their price target on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $162.94.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Blue Trust Inc. grew its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc boosted its holdings in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Quarry LP increased its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares in the last quarter. Covestor Ltd lifted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.